
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is well-positioned for future growth as enterprise behavioral health adoption and provider ROI continue to drive demand for their Deep TMS technology, particularly with the recent introduction of the SWIFT protocol. Furthermore, their shift towards a recurring-revenue model and strong financials, including a large cash balance and expected doubling of bottom-line results in 2026, provide solid support for continued organic investment and commercial execution. Despite risks to price target achievement, including slower uptake and expansion into new indications, the sales multiple-driven approach yields a 12-month price target of $17 per share, with a total firm value of ~$730M.
Bears say
BrainsWay is a leader in the field of advanced noninvasive neurostimulation treatments for mental health disorders, but its financial outlook is concerning. Despite its strong competitive position and extensive infrastructure, the company has struggled to generate significant revenues and maintain profitability. Additionally, as a result of Valor Equity Partners' significantly stronger financial position following the SpaceX IPO, BrainsWay's support and investments from this key long-term investor may diminish or shift towards other companies, potentially impacting the company's growth prospects.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares